Cocrystal Pharma, Inc. (COCP): Submission of Matters to a Vote of Security Holders
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001412486 0001412486 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
Voting results confirm board composition and auditor ratification; Proposal 3 (adjournment) was moot due to sufficient votes.
Market read
This is a governance/process update with no new financial, clinical, or corporate transaction details.
What to watch
Check whether the elected directors or auditor change signals governance priorities, but this 8-K provides no qualitative rationale or strategic updates.
Background
The company filed an 8-K under Item 5.07 summarizing outcomes of its July 14, 2026 annual stockholders meeting.
Ticker impact
Cocrystal Pharma reported 2026 annual meeting voting results, including election of five directors and ratification of its auditor.
Likely limited near-term impact; any reaction would be small and sentiment-driven rather than fundamental.
The filing is procedural (board and auditor ratification). Proposal 3 was moot due to sufficient votes, and no new guidance, trial data, or transactions were disclosed.
Market effects
Minimal; routine governance disclosure for a biotech with no sector-wide regulatory or clinical read-through.
None indicated.
None indicated.
Counterpoint
If traders were positioned around governance uncertainty, the confirmed vote could reduce headline risk, but the filing still lacks new fundamentals.
Key entities
- companyCocrystal Pharma, Inc.
Nasdaq-listed biotech that reported annual meeting voting outcomes on Form 8-K.
- auditorWeinberg & Company
Independent registered public accounting firm ratified for the fiscal year ending December 31, 2026.
